Connect with us

Menopause

Work stress top trigger of perimenopause symptoms, says Health & Her report

Published

on

The menopause support platform Health & Her has found that 80 per cent of women reported at least one trigger of perimenopause symptoms, including stress, caffeine, alcohol, and sugar.

The research conducted on 55,047 women going through perimenopause has shown that 54 per cent of participants reported stress at work as a major trigger. Examples of work stressors might be meeting a tight deadline, presenting in front of clients, attending performance reviews and taking part in social events.

“There are an estimated three million women currently going through perimenopause in the UK,” says Dr Rebeccah Tomlinson, GP menopause specialist at Health & Her.

“Although symptoms are primarily due to falling sex hormone levels, many of these women are unaware of the way mental health, lifestyle and diet choices can trigger the frequency and severity of their perimenopause symptoms.

“The reason stress at work is cited so frequently by women is because oestrogen helps maintain cortisol levels, so when oestrogen levels start to drop things go out of balance. It then becomes a vicious circle. The more you stress, the more you experience mind, mood, and sleep problems.”

Health & Her research found stress of this nature highly correlated to mind and mood symptoms of perimenopause including anxiety, low mood, poor concentration, brain fog and memory loss.

With more than four million perimenopausal or menopausal women currently in the workplace and one in ten leaving the workplace, finding ways to help them manage stress to minimise triggering symptoms is vital.

The research confirms a link between stressful events and worse menopause symptoms. However, according to the report, it is not necessarily the event that exacerbates symptoms but how a woman responds to that event.

Just under half (47 per cent) of the women surveyed reported this as trigger alongside anxiety, poor concentration, memory loss and heart palpitations.

Two in five women reported they started to experience more sensitivity to caffeine as they progressed through perimenopause.

Dr Rebeccah says this happens due to the caffeine found in tea, coffee and energy drinks that accelerates the nervous system, increases alertness, and interferes with the absorption of vitamins and minerals.

“Whilst it might seem like a good pick me up after a bad night’s sleep, caffeine can have a detrimental effect on sleep, causing insomnia which is one of the most common symptoms of perimenopause,” she adds.

Additionally, four in ten women found that they experienced an issue with alcohol tolerance.

Alcohol causes the blood vessels to dilate and raise the internal body temperature, leading to more hot flushes and night sweats, higher levels of cortisol, disrupted sleep, mood swings and increased dehydration.

Sugar posed a moderate issue for one third of the women. Sugary snacks are known to cause rapid high spikes in blood sugar levels.

High blood sugar, insulin resistance and metabolic syndrome are linked to hot flushes in perimenopausal women while dips in blood sugar can impact energy and mood levels. These spikes and dips can lead to a cycle of snacking on quick fix foods that can exacerbate menopausal weight gain and other symptoms such as bloating, digestive issues and memory loss, the researchers say.

Kate Bache, co-founder at Health & Her, says: “Seeing stress featuring twice in the top five triggers, it’s no wonder 15 per cent of women experiencing perimenopausal women have called in sick due to their symptoms.

“Women are struggling to perform at their job, due to the severity of their symptoms and lack of support.

“Almost a quarter of perimenopausal women surveyed admitted to making mistakes at work, while six per cent had to skip meetings to deal with their symptoms.”

Bache’s Health & Her aims to support perimenopausal and menopausal women through its Employer Menopause Support Plan.

The package offers clinic access to menopause-specialist GPs, advice, managerial and employee training, digital tools and webinars to help women track and manage menopause symptoms and support the employees who work with them.

“Businesses need to learn to adapt, create a space and culture that supports perimenopausal women to retain them in the workplace,” says Bache.

“These women are at a point in their lives where they have the experience, talent, and skills to positively contribute to the workforce. By offering the right help and developing the right plan around they will be able to continue to progress in their careers, rather leaving due to their symptoms.”

Menopause

Women with ADHD almost twice as likely to experience perimenopause symptoms, study finds

Published

on

Women with ADHD are nearly twice as likely to experience perimenopause symptoms compared with women without ADHD, new research has revealed.

The study reported 54 per cent of women with attention deficit hyperactivity disorder had perimenopausal symptoms, compared with 30 per cent without the condition.

Among perimenopausal women with ADHD, 59 per cent reported psychological symptoms such as anxiety, low mood, irritability and fatigue.

Physical symptoms, including hot flushes, headaches or palpitations (a rapid or irregular heartbeat), occurred in 30 per cent with ADHD versus 14 per cent without.

Published in 2025, the research also found symptoms tended to start earlier for women with ADHD, peaking around ages 35 to 39, while those without ADHD reported their most severe symptoms around age 45.

The study suggests two explanations for the increased burden among women with ADHD.

Firstly, anxiety and lower socio-economic status are known risk factors for perimenopausal symptoms; both are more common among women with ADHD and chronic stress may amplify risk.

Secondly, oestrogen helps modulate ADHD symptoms.

Women with ADHD are at higher risk of premenstrual dysphoric disorder (PMDD) and other cycle-related issues because ADHD symptoms can intensify when oestrogen levels fall.

During perimenopause, oestrogen naturally declines, so women with ADHD may experience both typical perimenopausal symptoms and a worsening of ADHD symptoms at the same time.

The research also found a higher prevalence of lifetime post-traumatic stress disorder (PTSD) symptoms among women with ADHD.

When this factor was accounted for, women with ADHD who did not have PTSD still faced increased risks, though both risk and symptom intensity were reduced.

These findings suggest that interventions which reduce chronic stress and inflammatory responses could help women with ADHD navigate perimenopause more effectively.

Continue Reading

Entrepreneur

Midi Health closes US$100m Series D

Published

on

Midi Health has closed a US$100m Series D, lifting the menopause care provider to a valuation above US$1bn and achieving unicorn status.

The company, originally focused on virtual menopause care, says it will expand to what it calls lifelong care, adding cardiology, obesity management, autoimmune survivorship and longevity services.

Joanna Strober is co-founder and chief executive officer of Midi Health.

She said: “This is validation for the movement we’re leading.

“Women’s health has been treated like an afterthought for too long.”

Midi reports it now sees more than 25,000 patients per week and has insurance coverage reaching 45 million women nationwide.

To support scale, the firm is rolling out a proprietary artificial intelligence engine intended to slot into clinical workflows.

It analyses patient charts before virtual visits to help personalise care, automates triage and documentation, and reviews data on midlife women to refine protocols.

The company has also strengthened its leadership. Jason Wheeler, formerly in senior finance roles at Tesla and Google, has been appointed chief financial officer. He joins chief marketing officer Melissa Waters, previously at Meta and Lyft, and chief commercial officer Matt Cook.

Each year, about two million women in the US enter menopause.

Untreated symptoms are estimated to cost the economy US$25bn annually.

Continue Reading

Menopause

IBSA UK launches non-hormonal injectable for menopause symptoms

Published

on

IBSA UK has introduced Hyaluxelle, a non-hormonal menopause treatment for vulvo-vaginal atrophy, easing vaginal dryness and pain during intercourse.

Hyaluxelle is given as deep intradermal injections to the vulvar vestibule, the area at the vaginal opening, in two sessions one month apart, followed by clinical reassessment.

IBSA UK is the UK subsidiary of Swiss pharmaceutical company IBSA.

Vulvo-vaginal atrophy is a key feature of genitourinary syndrome of menopause, a long-term condition caused by low oestrogen that affects genital, urinary and sexual health.

At least half of post-menopausal women are affected, yet many do not seek help, often assuming symptoms are part of ageing.

The condition stems from thinning and drying of vaginal and vulval tissues linked to low oestrogen, leading to symptoms such as dryness, discomfort, altered pH and pain during intercourse.

Hyaluxelle combines high and low molecular weight hyaluronic acid, a moisture-retaining substance found naturally in the body.

The company says this creates a lower-viscosity injection at what it describes as the highest concentration available in the UK, supporting tissue hydration, firmness and elasticity.

The formulation is said to rehydrate the vulvar vestibule and create conditions for restoring tissue structure through collagen and elastin production.

Clinical studies indicate Hyaluxelle improves several vulvo-vaginal symptoms, including reductions in discomfort and pain during intercourse.

Studies also report gains in sexual function domains and a positive trend in some aspects of health-related quality of life.

Histological analyses suggest increased epithelial thickness, enhanced tissue regeneration and reduced inflammatory infiltration after the procedure. In studies, the treatment was well tolerated with no reported major complications.

Joanna, a 59-year-old woman living with severe symptoms, described the personal impact of delayed diagnosis.

She said: “I lived for years with pain, UTIs, cystitis and a loss of sensation, but every visit to my GP, even a female GP, was treated as a bladder issue.

“Nobody suggested it might be linked to the menopause or joined the dots, and none of the treatments I was given helped. Without the right information or support, I became desperate for answers.

“The symptoms affected everything, what I wore, how I exercised, how I slept, but the hardest part was the impact on intimacy with my husband.

“I withdrew from our relationship because I was scared sex would hurt, and the loss of closeness was devastating, and I no longer felt like myself.

“Women deserve clear explanations and real options when their symptoms are not getting better.”

IBSA says Hyaluxelle offers clinicians an option for women whose symptoms persist despite first-line therapies, or for those who cannot receive or choose not to receive hormonal treatments.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.